Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (71-80 of 387) with videos related to

Pageof 39
Sort By:
Cancer|February 19, 2010
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationClive S Zent, Betsy R LaPlant, Patrick B Johnston, et al.
Blood|July 2, 2011
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphomaZhi-Zhang Yang, Deanna M Grote, Steven C Ziesmer, et al.
Leukemia & Lymphoma|March 13, 2023
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemiaMatteo Passerini, Tamar Ratishvili, Jonathon M Monroe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphomaThomas E Witzig, Christine A White, Leo I Gordon, et al.
American Journal of Hematology|March 7, 2016
Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myelomaJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
The Journal of Biological Chemistry|April 2, 2011
GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironmentSherine F Elsawa, Luciana L Almada, Steven C Ziesmer, et al.
Leukemia & Lymphoma|May 24, 2011
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportThomas E Witzig, Paul Fishkin, Leo I Gordon, et al.
International Journal of Dermatology|July 9, 2002
Treatment of late-stage Sézary syndrome with 2-ChlorodeoxyadenosineSaskia A Bouwhuis, Rokea A el-Azhary, Marian T McEvoy, et al.
Blood|November 17, 2007
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphomaLinfeng Chen, Stefano Monti, Przemyslaw Juszczynski, et al.
The Journal of Clinical Investigation|March 20, 2012
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaZhi-Zhang Yang, Deanna M Grote, Steven C Ziesmer, et al.
Pageof 39

Showing results (71-80 of 387) with videos related to

Sort By:
Pageof 39
Cancer|February 19, 2010
The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulationClive S Zent, Betsy R LaPlant, Patrick B Johnston, et al.
Blood|July 2, 2011
Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphomaZhi-Zhang Yang, Deanna M Grote, Steven C Ziesmer, et al.
Leukemia & Lymphoma|March 13, 2023
Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemiaMatteo Passerini, Tamar Ratishvili, Jonathon M Monroe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphomaThomas E Witzig, Christine A White, Leo I Gordon, et al.
American Journal of Hematology|March 7, 2016
Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myelomaJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
The Journal of Biological Chemistry|April 2, 2011
GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironmentSherine F Elsawa, Luciana L Almada, Steven C Ziesmer, et al.
Leukemia & Lymphoma|May 24, 2011
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference reportThomas E Witzig, Paul Fishkin, Leo I Gordon, et al.
International Journal of Dermatology|July 9, 2002
Treatment of late-stage Sézary syndrome with 2-ChlorodeoxyadenosineSaskia A Bouwhuis, Rokea A el-Azhary, Marian T McEvoy, et al.
Blood|November 17, 2007
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphomaLinfeng Chen, Stefano Monti, Przemyslaw Juszczynski, et al.
The Journal of Clinical Investigation|March 20, 2012
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaZhi-Zhang Yang, Deanna M Grote, Steven C Ziesmer, et al.
Pageof 39